In summary, elevation of endogenous EETs by overexpression of CYP2J2 and sEH inhibition, as well as EET analogs, showed protective effects against cardiac remodeling, which was mediated mainly by prohibiting inflammation, apoptosis, fibrosis, and cardiac hypertrophy and promoting angiogenesis. The gene discussed is EPHX2; the disease is cardiac hypertrophy.